(S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine
• 英文别名: (S)-1-(2’-(trifluoromethyl)-[3,4’-bipyridin]-6-yl)ethanamine；(S)-1-(2'-(trifluoromethyl)-[ 3,4'-bipyridyl]-6-yl)ethylamine；(1S)-1-[5-[2-(trifluoromethyl)pyridin-4-yl]pyridin-2-yl]ethanamine
• 化学式: C₁₃H₁₂F₃N₃
• 分子量: 267.254
• InChiKey: PQFVOWGSPGRIBZ-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-1-(2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethanamine 、 (R)-4-((S)-1-fluoroethyl)-3-(2-fluoropyrimidin-4-yl)oxazolidin-2-one 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 以32 mg的产率得到(R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(2’-(trifluoromethyl)-[3,4’-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one
  参考文献：
  名称：

  [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  [FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE

  摘要：

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。

  公开号：

  WO2014141104A1

文献信息

• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：NOVARTIS AG

  公开号：US20150152093A1

  公开（公告）日：2015-06-04

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2a , R 2b and R 3 -R 7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及一种公式(I)或其药学上可接受的盐，其中R1、R2a、R2b和R3-R7如下。该发明还涉及含有公式(I)化合物的组合物，并且涉及使用这些化合物来抑制具有新型活性的突变IDH蛋白质。该发明进一步涉及使用公式(I)化合物来治疗与这种突变IDH蛋白质相关的疾病或障碍，包括但不限于细胞增殖障碍，如癌症。
• 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
  申请人：Caferro Thomas Raymond

  公开号：US09434719B2

  公开（公告）日：2016-09-06

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  本发明涉及一种公式(I)或其药学上可接受的盐，其中R1，R2a，R2b和R3-R7如下。本发明还涉及含有公式(I)化合物的组合物，并且涉及使用这种化合物来抑制具有新异构酶活性的突变IDH蛋白质。本发明进一步涉及使用公式(I)化合物来治疗与这种突变IDH蛋白质相关的疾病或障碍，包括但不限于细胞增殖障碍，如癌症。
• COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Haihe Pharmaceutical Co., Ltd.

  公开号：EP3434674A1

  公开（公告）日：2019-01-30

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。
• Compound having mutant IDH inhibitory activity, preparation method and use thereof
  申请人：SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.

  公开号：US10682352B2

  公开（公告）日：2020-06-16

  Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof. In particular, provided in the present invention are the compound as shown in formula (I), a stereoisomer, a racemic body or a pharmaceutically acceptable salt thereof, and the use thereof in preparing drugs for preventing and treating diseases related to IDH mutation

  本发明提供了一种具有预防和治疗 IDH 突变相关疾病效果的化合物及其制备方法和用途。特别是，本发明提供了式 (I) 所示的化合物、其立体异构体、外消旋体或药学上可接受的盐，以及其在制备预防和治疗 IDH 突变相关疾病的药物中的用途。
• [EN] COMPOUND HAVING MUTANT IDH INHIBITORY ACTIVITY, PREPARATION METHOD AND USE THEREOF<br/>[FR] COMPOSÉ AYANT UNE ACTIVITÉ INHIBITRICE DE L'IDH MUTÉE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 一种具有突变型IDH抑制活性的化合物、其制备方法及用途
  申请人：SHANGHAI HAIHE PHARMACEUTICAL CO LTD

  公开号：WO2017162133A1

  公开（公告）日：2017-09-28

  本发明提供了一种具有预防和治疗与IDH突变相关的疾病的化合物、其制备方法和用途。具体地，本发明提供了式(I)化合物、其立体异构体、外消旋体、或其药学上可接受的盐，并提供了其在制备用于预防和治疗与IDH突变相关的疾病的药物中的应用。